Skip to main content
McMaster University Menu Search

Bmi1 in Recurrent Pediatric Medulloblastoma

Providing the foundation for devising clinical trials to further investigate PTC-028 as a therapeutic option for the treatment of recurrent medulloblastoma.

Medulloblastoma (MB) is the most frequent malignant brain tumour in children. Currently, therapeutic options for recurrent MB are limited. Previous studies in the Singh Lab have revealed the up-regulation of known stem cell markers, such as Bmi1, in the most aggressive subset of MB, also known as group 3 MB.

Through a partnership with PTC Therapeutics, a pharmaceutical company focused on the development of small molecule inhibitors, we are testing a range of novel compounds for their effectiveness in treating recurrent MB.



Sheila Singh

Sheila Singh

Principal Investigator